

Global Tumor Immunity Therapy Market Research Report 2025(Status and Outlook)

<https://marketpublishers.com/r/G3FF11053685EN.html>

Date: September 2025

Pages: 158

Price: US\$ 3,200.00 (Single User License)

ID: G3FF11053685EN

Abstracts

Tumor immunity therapy, also called cancer immunotherapy, refers to a class of treatments that leverage the body's own immune system to recognize, attack, and eliminate cancer cells. This approach includes various modalities such as immune checkpoint inhibitors (e.g., PD-1/PD-L1 and CTLA-4 inhibitors), CAR-T cell therapies, cancer vaccines, oncolytic viruses, and cytokine therapies. By either stimulating immune responses or removing suppressive mechanisms that tumors exploit, these therapies aim to provide durable, targeted antitumor effects with the potential for long-term remission, distinguishing them from traditional treatments like chemotherapy and radiation, which directly target cancer cells but often cause broader systemic toxicity. The global market for tumor immunity therapy is expanding rapidly, driven by rising cancer incidence, advancements in biotechnology, and increasing regulatory approvals for novel immunotherapies. Key players, including pharmaceutical giants and specialized biotech firms, are heavily investing in R&D to enhance therapeutic efficacy, reduce side effects, and expand applicable cancer types. The market is characterized by intense competition, strategic collaborations, and a growing focus on combination therapies to overcome resistance mechanisms. Geographically, North America leads in adoption and expenditure, followed by Europe and Asia-Pacific, where emerging economies are gradually improving access amid evolving healthcare infrastructure and reimbursement policies. Despite high costs and challenges related to patient stratification and immune-related adverse events, the segment is poised for sustained growth as personalized medicine and biomarker-driven approaches continue to refine treatment paradigms.

The global Tumor Immunity Therapy market size was estimated at USD 9450.0 million in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 18.50% during the forecast period.

This report offers a comprehensive and in-depth analysis of the global Tumor Immunity Therapy market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.

The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.

A significant focus of this report lies in the competitive landscape of the global Tumor Immunity Therapy market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.

In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Tumor Immunity Therapy market.

Global Tumor Immunity Therapy Market: Market Segmentation Analysis

This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.

A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.

Key Company

Bristol-Myers Squibb
Merck & Co.Inc.
Roche AG
AstraZeneca
Plc
Sanofi S.A.
Dendreon Pharmaceuticals
Novartis
Gilead Sciences Inc.
IMVAQ Therapeutics
Arch Oncology
Juno Therapeutics
Refuge
Lepu Biopharma
Genoimmune
TCR Cure

Market Segmentation (by Type)

Immune Checkpoint Inhibitor
Cytokine Immunotherapy
Cancer Vaccine
Car-t Cell Therapy
Others

Market Segmentation (by Application)

Hospital
Clinic

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Tumor Immunity Therapy Market

Overview of the regional outlook of the Tumor Immunity Therapy Market:

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Tumor Immunity Therapy Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Tumor Immunity Therapy, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.

Chapter 13 is the main points and conclusions of the report.

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your

competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

1.1 Market Definition and Statistical Scope of Tumor Immunity Therapy

1.2 Key Market Segments

1.2.1 Tumor Immunity Therapy Segment by Type

1.2.2 Tumor Immunity Therapy Segment by Application

1.3 Methodology & Sources of Information

1.3.1 Research Methodology

1.3.2 Research Process

1.3.3 Market Breakdown and Data Triangulation

1.3.4 Base Year

1.3.5 Report Assumptions & Caveats

2 TUMOR IMMUNITY THERAPY MARKET OVERVIEW

2.1 Global Market Overview

2.1.1 Global Tumor Immunity Therapy Market Size (M USD) Estimates and Forecasts (2020-2033)

2.1.2 Global Tumor Immunity Therapy Sales Estimates and Forecasts (2020-2033)

2.2 Market Segment Executive Summary

2.3 Global Market Size by Region

3 TUMOR IMMUNITY THERAPY MARKET COMPETITIVE LANDSCAPE

3.1 Company Assessment Quadrant

3.2 Global Tumor Immunity Therapy Product Life Cycle

3.3 Global Tumor Immunity Therapy Sales by Manufacturers (2020-2025)

3.4 Global Tumor Immunity Therapy Revenue Market Share by Manufacturers (2020-2025)

3.5 Tumor Immunity Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.6 Global Tumor Immunity Therapy Average Price by Manufacturers (2020-2025)

3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types

3.8 Tumor Immunity Therapy Market Competitive Situation and Trends

3.8.1 Tumor Immunity Therapy Market Concentration Rate

3.8.2 Global 5 and 10 Largest Tumor Immunity Therapy Players Market Share by Revenue

3.8.3 Mergers & Acquisitions, Expansion

4 TUMOR IMMUNITY THERAPY INDUSTRY CHAIN ANALYSIS

4.1 Tumor Immunity Therapy Industry Chain Analysis

4.2 Market Overview of Key Raw Materials

4.3 Midstream Market Analysis

4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF TUMOR IMMUNITY THERAPY MARKET

5.1 Key Development Trends

5.2 Driving Factors

5.3 Market Challenges

5.4 Industry News

5.4.1 New Product Developments

5.4.2 Mergers & Acquisitions

5.4.3 Expansions

5.4.4 Collaboration/Supply Contracts

5.5 PEST Analysis

5.5.1 Industry Policies Analysis

5.5.2 Economic Environment Analysis

5.5.3 Social Environment Analysis

5.5.4 Technological Environment Analysis

5.6 Global Tumor Immunity Therapy Market Porter's Five Forces Analysis

5.6.1 Global Trade Frictions

5.6.2 U.S. Tariff Policy ? April 2025

5.6.3 Global Trade Frictions and Their Impacts to Tumor Immunity Therapy Market

5.7 ESG Ratings of Leading Companies

6 TUMOR IMMUNITY THERAPY MARKET SEGMENTATION BY TYPE

6.1 Evaluation Matrix of Segment Market Development Potential (Type)

6.2 Global Tumor Immunity Therapy Sales Market Share by Type (2020-2025)

6.3 Global Tumor Immunity Therapy Market Size Market Share by Type (2020-2025)

6.4 Global Tumor Immunity Therapy Price by Type (2020-2025)

7 TUMOR IMMUNITY THERAPY MARKET SEGMENTATION BY APPLICATION

- 7.1 Evaluation Matrix of Segment Market Development Potential (Application)
- 7.2 Global Tumor Immunity Therapy Market Sales by Application (2020-2025)
- 7.3 Global Tumor Immunity Therapy Market Size (M USD) by Application (2020-2025)
- 7.4 Global Tumor Immunity Therapy Sales Growth Rate by Application (2020-2025)

8 TUMOR IMMUNITY THERAPY MARKET SALES BY REGION

- 8.1 Global Tumor Immunity Therapy Sales by Region
 - 8.1.1 Global Tumor Immunity Therapy Sales by Region
 - 8.1.2 Global Tumor Immunity Therapy Sales Market Share by Region
- 8.2 Global Tumor Immunity Therapy Market Size by Region
 - 8.2.1 Global Tumor Immunity Therapy Market Size by Region
 - 8.2.2 Global Tumor Immunity Therapy Market Size Market Share by Region
- 8.3 North America
 - 8.3.1 North America Tumor Immunity Therapy Sales by Country
 - 8.3.2 North America Tumor Immunity Therapy Market Size by Country
 - 8.3.3 U.S. Market Overview
 - 8.3.4 Canada Market Overview
 - 8.3.5 Mexico Market Overview
- 8.4 Europe
 - 8.4.1 Europe Tumor Immunity Therapy Sales by Country
 - 8.4.2 Europe Tumor Immunity Therapy Market Size by Country
 - 8.4.3 Germany Market Overview
 - 8.4.4 France Market Overview
 - 8.4.5 U.K. Market Overview
 - 8.4.6 Italy Market Overview
 - 8.4.7 Spain Market Overview
- 8.5 Asia Pacific
 - 8.5.1 Asia Pacific Tumor Immunity Therapy Sales by Region
 - 8.5.2 Asia Pacific Tumor Immunity Therapy Market Size by Region
 - 8.5.3 China Market Overview
 - 8.5.4 Japan Market Overview
 - 8.5.5 South Korea Market Overview
 - 8.5.6 India Market Overview
 - 8.5.7 Southeast Asia Market Overview
- 8.6 South America
 - 8.6.1 South America Tumor Immunity Therapy Sales by Country
 - 8.6.2 South America Tumor Immunity Therapy Market Size by Country

8.6.3 Brazil Market Overview

8.6.4 Argentina Market Overview

8.6.5 Columbia Market Overview

8.7 Middle East and Africa

8.7.1 Middle East and Africa Tumor Immunity Therapy Sales by Region

8.7.2 Middle East and Africa Tumor Immunity Therapy Market Size by Region

8.7.3 Saudi Arabia Market Overview

8.7.4 UAE Market Overview

8.7.5 Egypt Market Overview

8.7.6 Nigeria Market Overview

8.7.7 South Africa Market Overview

9 TUMOR IMMUNITY THERAPY MARKET PRODUCTION BY REGION

9.1 Global Production of Tumor Immunity Therapy by Region(2020-2025)

9.2 Global Tumor Immunity Therapy Revenue Market Share by Region (2020-2025)

9.3 Global Tumor Immunity Therapy Production, Revenue, Price and Gross Margin (2020-2025)

9.4 North America Tumor Immunity Therapy Production

9.4.1 North America Tumor Immunity Therapy Production Growth Rate (2020-2025)

9.4.2 North America Tumor Immunity Therapy Production, Revenue, Price and Gross Margin (2020-2025)

9.5 Europe Tumor Immunity Therapy Production

9.5.1 Europe Tumor Immunity Therapy Production Growth Rate (2020-2025)

9.5.2 Europe Tumor Immunity Therapy Production, Revenue, Price and Gross Margin (2020-2025)

9.6 Japan Tumor Immunity Therapy Production (2020-2025)

9.6.1 Japan Tumor Immunity Therapy Production Growth Rate (2020-2025)

9.6.2 Japan Tumor Immunity Therapy Production, Revenue, Price and Gross Margin (2020-2025)

9.7 China Tumor Immunity Therapy Production (2020-2025)

9.7.1 China Tumor Immunity Therapy Production Growth Rate (2020-2025)

9.7.2 China Tumor Immunity Therapy Production, Revenue, Price and Gross Margin (2020-2025)

10 KEY COMPANIES PROFILE

10.1 Bristol-Myers Squibb

10.1.1 Bristol-Myers Squibb Basic Information

- 10.1.2 Bristol-Myers Squibb Tumor Immunity Therapy Product Overview
- 10.1.3 Bristol-Myers Squibb Tumor Immunity Therapy Product Market Performance
- 10.1.4 Bristol-Myers Squibb Business Overview
- 10.1.5 Bristol-Myers Squibb SWOT Analysis
- 10.1.6 Bristol-Myers Squibb Recent Developments
- 10.2 Merck and Co.Inc.
 - 10.2.1 Merck and Co.Inc. Basic Information
 - 10.2.2 Merck and Co.Inc. Tumor Immunity Therapy Product Overview
 - 10.2.3 Merck and Co.Inc. Tumor Immunity Therapy Product Market Performance
 - 10.2.4 Merck and Co.Inc. Business Overview
 - 10.2.5 Merck and Co.Inc. SWOT Analysis
 - 10.2.6 Merck and Co.Inc. Recent Developments
- 10.3 Roche AG
 - 10.3.1 Roche AG Basic Information
 - 10.3.2 Roche AG Tumor Immunity Therapy Product Overview
 - 10.3.3 Roche AG Tumor Immunity Therapy Product Market Performance
 - 10.3.4 Roche AG Business Overview
 - 10.3.5 Roche AG SWOT Analysis
 - 10.3.6 Roche AG Recent Developments
- 10.4 AstraZeneca
 - 10.4.1 AstraZeneca Basic Information
 - 10.4.2 AstraZeneca Tumor Immunity Therapy Product Overview
 - 10.4.3 AstraZeneca Tumor Immunity Therapy Product Market Performance
 - 10.4.4 AstraZeneca Business Overview
 - 10.4.5 AstraZeneca Recent Developments
- 10.5 Plc
 - 10.5.1 Plc Basic Information
 - 10.5.2 Plc Tumor Immunity Therapy Product Overview
 - 10.5.3 Plc Tumor Immunity Therapy Product Market Performance
 - 10.5.4 Plc Business Overview
 - 10.5.5 Plc Recent Developments
- 10.6 Sanofi S.A.
 - 10.6.1 Sanofi S.A. Basic Information
 - 10.6.2 Sanofi S.A. Tumor Immunity Therapy Product Overview
 - 10.6.3 Sanofi S.A. Tumor Immunity Therapy Product Market Performance
 - 10.6.4 Sanofi S.A. Business Overview
 - 10.6.5 Sanofi S.A. Recent Developments
- 10.7 Dendreon Pharmaceuticals
 - 10.7.1 Dendreon Pharmaceuticals Basic Information

- 10.7.2 Dendreon Pharmaceuticals Tumor Immunity Therapy Product Overview
- 10.7.3 Dendreon Pharmaceuticals Tumor Immunity Therapy Product Market Performance
- 10.7.4 Dendreon Pharmaceuticals Business Overview
- 10.7.5 Dendreon Pharmaceuticals Recent Developments
- 10.8 Novartis
 - 10.8.1 Novartis Basic Information
 - 10.8.2 Novartis Tumor Immunity Therapy Product Overview
 - 10.8.3 Novartis Tumor Immunity Therapy Product Market Performance
 - 10.8.4 Novartis Business Overview
 - 10.8.5 Novartis Recent Developments
- 10.9 Gilead Sciences Inc.
 - 10.9.1 Gilead Sciences Inc. Basic Information
 - 10.9.2 Gilead Sciences Inc. Tumor Immunity Therapy Product Overview
 - 10.9.3 Gilead Sciences Inc. Tumor Immunity Therapy Product Market Performance
 - 10.9.4 Gilead Sciences Inc. Business Overview
 - 10.9.5 Gilead Sciences Inc. Recent Developments
- 10.10 IMVAQ Therapeutics
 - 10.10.1 IMVAQ Therapeutics Basic Information
 - 10.10.2 IMVAQ Therapeutics Tumor Immunity Therapy Product Overview
 - 10.10.3 IMVAQ Therapeutics Tumor Immunity Therapy Product Market Performance
 - 10.10.4 IMVAQ Therapeutics Business Overview
 - 10.10.5 IMVAQ Therapeutics Recent Developments
- 10.11 Arch Oncology
 - 10.11.1 Arch Oncology Basic Information
 - 10.11.2 Arch Oncology Tumor Immunity Therapy Product Overview
 - 10.11.3 Arch Oncology Tumor Immunity Therapy Product Market Performance
 - 10.11.4 Arch Oncology Business Overview
 - 10.11.5 Arch Oncology Recent Developments
- 10.12 Juno Therapeutics
 - 10.12.1 Juno Therapeutics Basic Information
 - 10.12.2 Juno Therapeutics Tumor Immunity Therapy Product Overview
 - 10.12.3 Juno Therapeutics Tumor Immunity Therapy Product Market Performance
 - 10.12.4 Juno Therapeutics Business Overview
 - 10.12.5 Juno Therapeutics Recent Developments
- 10.13 Refuge
 - 10.13.1 Refuge Basic Information
 - 10.13.2 Refuge Tumor Immunity Therapy Product Overview
 - 10.13.3 Refuge Tumor Immunity Therapy Product Market Performance

- 10.13.4 Refuge Business Overview
- 10.13.5 Refuge Recent Developments
- 10.14 Lepu Biopharma
 - 10.14.1 Lepu Biopharma Basic Information
 - 10.14.2 Lepu Biopharma Tumor Immunity Therapy Product Overview
 - 10.14.3 Lepu Biopharma Tumor Immunity Therapy Product Market Performance
 - 10.14.4 Lepu Biopharma Business Overview
 - 10.14.5 Lepu Biopharma Recent Developments
- 10.15 Genoimmune
 - 10.15.1 Genoimmune Basic Information
 - 10.15.2 Genoimmune Tumor Immunity Therapy Product Overview
 - 10.15.3 Genoimmune Tumor Immunity Therapy Product Market Performance
 - 10.15.4 Genoimmune Business Overview
 - 10.15.5 Genoimmune Recent Developments
- 10.16 TCR Cure
 - 10.16.1 TCR Cure Basic Information
 - 10.16.2 TCR Cure Tumor Immunity Therapy Product Overview
 - 10.16.3 TCR Cure Tumor Immunity Therapy Product Market Performance
 - 10.16.4 TCR Cure Business Overview
 - 10.16.5 TCR Cure Recent Developments

11 TUMOR IMMUNITY THERAPY MARKET FORECAST BY REGION

- 11.1 Global Tumor Immunity Therapy Market Size Forecast
- 11.2 Global Tumor Immunity Therapy Market Forecast by Region
 - 11.2.1 North America Market Size Forecast by Country
 - 11.2.2 Europe Tumor Immunity Therapy Market Size Forecast by Country
 - 11.2.3 Asia Pacific Tumor Immunity Therapy Market Size Forecast by Region
 - 11.2.4 South America Tumor Immunity Therapy Market Size Forecast by Country
 - 11.2.5 Middle East and Africa Forecasted Sales of Tumor Immunity Therapy by Country

12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2033)

- 12.1 Global Tumor Immunity Therapy Market Forecast by Type (2026-2033)
 - 12.1.1 Global Forecasted Sales of Tumor Immunity Therapy by Type (2026-2033)
 - 12.1.2 Global Tumor Immunity Therapy Market Size Forecast by Type (2026-2033)
 - 12.1.3 Global Forecasted Price of Tumor Immunity Therapy by Type (2026-2033)
- 12.2 Global Tumor Immunity Therapy Market Forecast by Application (2026-2033)

12.2.1 Global Tumor Immunity Therapy Sales (K MT) Forecast by Application

12.2.2 Global Tumor Immunity Therapy Market Size (M USD) Forecast by Application
(2026-2033)

13 CONCLUSION AND KEY FINDINGS

List Of Tables

LIST OF TABLES

Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Tumor Immunity Therapy Market Size Comparison by Region (M USD)
Table 5. Global Tumor Immunity Therapy Sales (K MT) by Manufacturers (2020-2025)
Table 6. Global Tumor Immunity Therapy Sales Market Share by Manufacturers (2020-2025)
Table 7. Global Tumor Immunity Therapy Revenue (M USD) by Manufacturers (2020-2025)
Table 8. Global Tumor Immunity Therapy Revenue Share by Manufacturers (2020-2025)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor Immunity Therapy as of 2024)
Table 10. Global Market Tumor Immunity Therapy Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 11. Manufacturers? Manufacturing Sites, Areas Served
Table 12. Manufacturers? Product Type
Table 13. Global Tumor Immunity Therapy Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Market Overview of Key Raw Materials
Table 16. Midstream Market Analysis
Table 17. Downstream Customer Analysis
Table 18. Key Development Trends
Table 19. Driving Factors
Table 20. Tumor Immunity Therapy Market Challenges
Table 21. Goldman Sachs' forecast real GDP growth rate for 2024-2026
Table 22. S&P Global ' Forecast Real GDP Growth Rate For 2024-2027
Table 23. World Bank ' Forecast Real GDP Growth Rate For 2024-2026
Table 24. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 25. Global Tumor Immunity Therapy Sales by Type (K MT)
Table 26. Global Tumor Immunity Therapy Market Size by Type (M USD)
Table 27. Global Tumor Immunity Therapy Sales (K MT) by Type (2020-2025)
Table 28. Global Tumor Immunity Therapy Sales Market Share by Type (2020-2025)

Table 29. Global Tumor Immunity Therapy Market Size (M USD) by Type (2020-2025)
Table 30. Global Tumor Immunity Therapy Market Size Share by Type (2020-2025)
Table 31. Global Tumor Immunity Therapy Price (USD/KG) by Type (2020-2025)
Table 32. Global Tumor Immunity Therapy Sales (K MT) by Application
Table 33. Global Tumor Immunity Therapy Market Size by Application
Table 34. Global Tumor Immunity Therapy Sales by Application (2020-2025) & (K MT)
Table 35. Global Tumor Immunity Therapy Sales Market Share by Application (2020-2025)
Table 36. Global Tumor Immunity Therapy Market Size by Application (2020-2025) & (M USD)
Table 37. Global Tumor Immunity Therapy Market Share by Application (2020-2025)
Table 38. Global Tumor Immunity Therapy Sales Growth Rate by Application (2020-2025)
Table 39. Global Tumor Immunity Therapy Sales by Region (2020-2025) & (K MT)
Table 40. Global Tumor Immunity Therapy Sales Market Share by Region (2020-2025)
Table 41. Global Tumor Immunity Therapy Market Size by Region (2020-2025) & (M USD)
Table 42. Global Tumor Immunity Therapy Market Size Market Share by Region (2020-2025)
Table 43. North America Tumor Immunity Therapy Sales by Country (2020-2025) & (K MT)
Table 44. North America Tumor Immunity Therapy Market Size by Country (2020-2025) & (M USD)
Table 45. Europe Tumor Immunity Therapy Sales by Country (2020-2025) & (K MT)
Table 46. Europe Tumor Immunity Therapy Market Size by Country (2020-2025) & (M USD)
Table 47. Asia Pacific Tumor Immunity Therapy Sales by Region (2020-2025) & (K MT)
Table 48. Asia Pacific Tumor Immunity Therapy Market Size by Region (2020-2025) & (M USD)
Table 49. South America Tumor Immunity Therapy Sales by Country (2020-2025) & (K MT)
Table 50. South America Tumor Immunity Therapy Market Size by Country (2020-2025) & (M USD)
Table 51. Middle East and Africa Tumor Immunity Therapy Sales by Region (2020-2025) & (K MT)
Table 52. Middle East and Africa Tumor Immunity Therapy Market Size by Region (2020-2025) & (M USD)
Table 53. Global Tumor Immunity Therapy Production (K MT) by Region(2020-2025)
Table 54. Global Tumor Immunity Therapy Revenue (US\$ Million) by Region

(2020-2025)

Table 55. Global Tumor Immunity Therapy Revenue Market Share by Region
(2020-2025)

Table 56. Global Tumor Immunity Therapy Production (K MT), Revenue (US\$ Million),
Price (USD/KG) and Gross Margin (2020-2025)

Table 57. North America Tumor Immunity Therapy Production (K MT), Revenue (US\$
Million), Price (USD/KG) and Gross Margin (2020-2025)

Table 58. Europe Tumor Immunity Therapy Production (K MT), Revenue (US\$ Million),
Price (USD/KG) and Gross Margin (2020-2025)

Table 59. Japan Tumor Immunity Therapy Production (K MT), Revenue (US\$ Million),
Price (USD/KG) and Gross Margin (2020-2025)

Table 60. China Tumor Immunity Therapy Production (K MT), Revenue (US\$ Million),
Price (USD/KG) and Gross Margin (2020-2025)

Table 61. Bristol-Myers Squibb Basic Information

Table 62. Bristol-Myers Squibb Tumor Immunity Therapy Product Overview

Table 63. Bristol-Myers Squibb Tumor Immunity Therapy Sales (K MT), Revenue (M
USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 64. Bristol-Myers Squibb Business Overview

Table 65. Bristol-Myers Squibb SWOT Analysis

Table 66. Bristol-Myers Squibb Recent Developments

Table 67. Merck and Co.Inc. Basic Information

Table 68. Merck and Co.Inc. Tumor Immunity Therapy Product Overview

Table 69. Merck and Co.Inc. Tumor Immunity Therapy Sales (K MT), Revenue (M
USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 70. Merck and Co.Inc. Business Overview

Table 71. Merck and Co.Inc. SWOT Analysis

Table 72. Merck and Co.Inc. Recent Developments

Table 73. Roche AG Basic Information

Table 74. Roche AG Tumor Immunity Therapy Product Overview

Table 75. Roche AG Tumor Immunity Therapy Sales (K MT), Revenue (M USD), Price
(USD/KG) and Gross Margin (2020-2025)

Table 76. Roche AG Business Overview

Table 77. Roche AG SWOT Analysis

Table 78. Roche AG Recent Developments

Table 79. AstraZeneca Basic Information

Table 80. AstraZeneca Tumor Immunity Therapy Product Overview

Table 81. AstraZeneca Tumor Immunity Therapy Sales (K MT), Revenue (M USD),
Price (USD/KG) and Gross Margin (2020-2025)

Table 82. AstraZeneca Business Overview

Table 83. AstraZeneca Recent Developments

Table 84. Plc Basic Information

Table 85. Plc Tumor Immunity Therapy Product Overview

Table 86. Plc Tumor Immunity Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 87. Plc Business Overview

Table 88. Plc Recent Developments

Table 89. Sanofi S.A. Basic Information

Table 90. Sanofi S.A. Tumor Immunity Therapy Product Overview

Table 91. Sanofi S.A. Tumor Immunity Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 92. Sanofi S.A. Business Overview

Table 93. Sanofi S.A. Recent Developments

Table 94. Dendreon Pharmaceuticals Basic Information

Table 95. Dendreon Pharmaceuticals Tumor Immunity Therapy Product Overview

Table 96. Dendreon Pharmaceuticals Tumor Immunity Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 97. Dendreon Pharmaceuticals Business Overview

Table 98. Dendreon Pharmaceuticals Recent Developments

Table 99. Novartis Basic Information

Table 100. Novartis Tumor Immunity Therapy Product Overview

Table 101. Novartis Tumor Immunity Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 102. Novartis Business Overview

Table 103. Novartis Recent Developments

Table 104. Gilead Sciences Inc. Basic Information

Table 105. Gilead Sciences Inc. Tumor Immunity Therapy Product Overview

Table 106. Gilead Sciences Inc. Tumor Immunity Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 107. Gilead Sciences Inc. Business Overview

Table 108. Gilead Sciences Inc. Recent Developments

Table 109. IMVAQ Therapeutics Basic Information

Table 110. IMVAQ Therapeutics Tumor Immunity Therapy Product Overview

Table 111. IMVAQ Therapeutics Tumor Immunity Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 112. IMVAQ Therapeutics Business Overview

Table 113. IMVAQ Therapeutics Recent Developments

Table 114. Arch Oncology Basic Information

Table 115. Arch Oncology Tumor Immunity Therapy Product Overview

Table 116. Arch Oncology Tumor Immunity Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 117. Arch Oncology Business Overview
Table 118. Arch Oncology Recent Developments
Table 119. Juno Therapeutics Basic Information
Table 120. Juno Therapeutics Tumor Immunity Therapy Product Overview
Table 121. Juno Therapeutics Tumor Immunity Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 122. Juno Therapeutics Business Overview
Table 123. Juno Therapeutics Recent Developments
Table 124. Refuge Basic Information
Table 125. Refuge Tumor Immunity Therapy Product Overview
Table 126. Refuge Tumor Immunity Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 127. Refuge Business Overview
Table 128. Refuge Recent Developments
Table 129. Lepu Biopharma Basic Information
Table 130. Lepu Biopharma Tumor Immunity Therapy Product Overview
Table 131. Lepu Biopharma Tumor Immunity Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 132. Lepu Biopharma Business Overview
Table 133. Lepu Biopharma Recent Developments
Table 134. Genoimmune Basic Information
Table 135. Genoimmune Tumor Immunity Therapy Product Overview
Table 136. Genoimmune Tumor Immunity Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 137. Genoimmune Business Overview
Table 138. Genoimmune Recent Developments
Table 139. TCR Cure Basic Information
Table 140. TCR Cure Tumor Immunity Therapy Product Overview
Table 141. TCR Cure Tumor Immunity Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 142. TCR Cure Business Overview
Table 143. TCR Cure Recent Developments
Table 144. Global Tumor Immunity Therapy Sales Forecast by Region (2026-2033) & (K MT)
Table 145. Global Tumor Immunity Therapy Market Size Forecast by Region (2026-2033) & (M USD)
Table 146. North America Tumor Immunity Therapy Sales Forecast by Country

(2026-2033) & (K MT)

Table 147. North America Tumor Immunity Therapy Market Size Forecast by Country (2026-2033) & (M USD)

Table 148. Europe Tumor Immunity Therapy Sales Forecast by Country (2026-2033) & (K MT)

Table 149. Europe Tumor Immunity Therapy Market Size Forecast by Country (2026-2033) & (M USD)

Table 150. Asia Pacific Tumor Immunity Therapy Sales Forecast by Region (2026-2033) & (K MT)

Table 151. Asia Pacific Tumor Immunity Therapy Market Size Forecast by Region (2026-2033) & (M USD)

Table 152. South America Tumor Immunity Therapy Sales Forecast by Country (2026-2033) & (K MT)

Table 153. South America Tumor Immunity Therapy Market Size Forecast by Country (2026-2033) & (M USD)

Table 154. Middle East and Africa Tumor Immunity Therapy Sales Forecast by Country (2026-2033) & (Units)

Table 155. Middle East and Africa Tumor Immunity Therapy Market Size Forecast by Country (2026-2033) & (M USD)

Table 156. Global Tumor Immunity Therapy Sales Forecast by Type (2026-2033) & (K MT)

Table 157. Global Tumor Immunity Therapy Market Size Forecast by Type (2026-2033) & (M USD)

Table 158. Global Tumor Immunity Therapy Price Forecast by Type (2026-2033) & (USD/KG)

Table 159. Global Tumor Immunity Therapy Sales (K MT) Forecast by Application (2026-2033)

Table 160. Global Tumor Immunity Therapy Market Size Forecast by Application (2026-2033) & (M USD)

List Of Figures

LIST OF FIGURES

- Figure 1. Product Picture of Tumor Immunity Therapy
- Figure 2. Data Triangulation
- Figure 3. Key Caveats
- Figure 4. Global Tumor Immunity Therapy Market Size (M USD), 2024-2033
- Figure 5. Global Tumor Immunity Therapy Market Size (M USD) (2020-2033)
- Figure 6. Global Tumor Immunity Therapy Sales (K MT) & (2020-2033)
- Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
- Figure 9. Evaluation Matrix of Regional Market Development Potential
- Figure 10. Tumor Immunity Therapy Market Size by Country (M USD)
- Figure 11. Company Assessment Quadrant
- Figure 12. Global Tumor Immunity Therapy Product Life Cycle
- Figure 13. Tumor Immunity Therapy Sales Share by Manufacturers in 2024
- Figure 14. Global Tumor Immunity Therapy Revenue Share by Manufacturers in 2024
- Figure 15. Tumor Immunity Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024
- Figure 16. Global Market Tumor Immunity Therapy Average Price (USD/KG) of Key Manufacturers in 2024
- Figure 17. The Global 5 and 10 Largest Players: Market Share by Tumor Immunity Therapy Revenue in 2024
- Figure 18. Industry Chain Map of Tumor Immunity Therapy
- Figure 19. Global Tumor Immunity Therapy Market PEST Analysis
- Figure 20. Global Tumor Immunity Therapy Market Porter's Five Forces Analysis
- Figure 21. Global Merchandise Trade as a Percentage Of GDP
- Figure 22. US - Imports of Goods by Country
- Figure 23. China Exports by Country
- Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
- Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 26. Global Tumor Immunity Therapy Market Share by Type
- Figure 27. Sales Market Share of Tumor Immunity Therapy by Type (2020-2025)
- Figure 28. Sales Market Share of Tumor Immunity Therapy by Type in 2024
- Figure 29. Market Size Share of Tumor Immunity Therapy by Type (2020-2025)
- Figure 30. Market Size Share of Tumor Immunity Therapy by Type in 2024
- Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
- Figure 32. Global Tumor Immunity Therapy Market Share by Application

Figure 33. Global Tumor Immunity Therapy Sales Market Share by Application (2020-2025)

Figure 34. Global Tumor Immunity Therapy Sales Market Share by Application in 2024

Figure 35. Global Tumor Immunity Therapy Market Share by Application (2020-2025)

Figure 36. Global Tumor Immunity Therapy Market Share by Application in 2024

Figure 37. Global Tumor Immunity Therapy Sales Growth Rate by Application (2020-2025)

Figure 38. Global Tumor Immunity Therapy Sales Market Share by Region (2020-2025)

Figure 39. Global Tumor Immunity Therapy Market Size Market Share by Region (2020-2025)

Figure 40. North America Tumor Immunity Therapy Sales and Growth Rate (2020-2025) & (K MT)

Figure 41. North America Tumor Immunity Therapy Sales and Growth Rate (2020-2025) & (K MT)

Figure 42. North America Tumor Immunity Therapy Sales Market Share by Country in 2024

Figure 43. North America Tumor Immunity Therapy Market Size and Growth Rate (2020-2025) & (M USD)

Figure 44. North America Tumor Immunity Therapy Market Size Market Share by Country in 2024

Figure 45. U.S. Tumor Immunity Therapy Sales and Growth Rate (2020-2025) & (K MT)

Figure 46. U.S. Tumor Immunity Therapy Market Size and Growth Rate (2020-2025) & (M USD)

Figure 47. Canada Tumor Immunity Therapy Sales (K MT) and Growth Rate (2020-2025)

Figure 48. Canada Tumor Immunity Therapy Market Size (M USD) and Growth Rate (2020-2025)

Figure 49. Mexico Tumor Immunity Therapy Sales (Units) and Growth Rate (2020-2025)

Figure 50. Mexico Tumor Immunity Therapy Market Size (Units) and Growth Rate (2020-2025)

Figure 51. Europe Tumor Immunity Therapy Sales and Growth Rate (2020-2025) & (K MT)

Figure 52. Europe Tumor Immunity Therapy Sales Market Share by Country in 2024

Figure 53. Europe Tumor Immunity Therapy Market Size and Growth Rate (2020-2025) & (M USD)

Figure 54. Europe Tumor Immunity Therapy Market Size Market Share by Country in 2024

Figure 55. Germany Tumor Immunity Therapy Sales and Growth Rate (2020-2025) & (K MT)

Figure 56. Germany Tumor Immunity Therapy Market Size and Growth Rate (2020-2025) & (M USD)

Figure 57. France Tumor Immunity Therapy Sales and Growth Rate (2020-2025) & (K MT)

Figure 58. France Tumor Immunity Therapy Market Size and Growth Rate (2020-2025) & (M USD)

Figure 59. U.K. Tumor Immunity Therapy Sales and Growth Rate (2020-2025) & (K MT)

Figure 60. U.K. Tumor Immunity Therapy Market Size and Growth Rate (2020-2025) & (M USD)

Figure 61. Italy Tumor Immunity Therapy Sales and Growth Rate (2020-2025) & (K MT)

Figure 62. Italy Tumor Immunity Therapy Market Size and Growth Rate (2020-2025) & (M USD)

Figure 63. Spain Tumor Immunity Therapy Sales and Growth Rate (2020-2025) & (K MT)

Figure 64. Spain Tumor Immunity Therapy Market Size and Growth Rate (2020-2025) & (M USD)

Figure 65. Asia Pacific Tumor Immunity Therapy Sales and Growth Rate (K MT)

Figure 66. Asia Pacific Tumor Immunity Therapy Sales Market Share by Region in 2024

Figure 67. Asia Pacific Tumor Immunity Therapy Market Size Market Share by Region in 2024

Figure 68. China Tumor Immunity Therapy Sales and Growth Rate (2020-2025) & (K MT)

Figure 69. China Tumor Immunity Therapy Market Size and Growth Rate (2020-2025) & (M USD)

Figure 70. Japan Tumor Immunity Therapy Sales and Growth Rate (2020-2025) & (K MT)

Figure 71. Japan Tumor Immunity Therapy Market Size and Growth Rate (2020-2025) & (M USD)

Figure 72. South Korea Tumor Immunity Therapy Sales and Growth Rate (2020-2025) & (K MT)

Figure 73. South Korea Tumor Immunity Therapy Market Size and Growth Rate (2020-2025) & (M USD)

Figure 74. India Tumor Immunity Therapy Sales and Growth Rate (2020-2025) & (K MT)

Figure 75. India Tumor Immunity Therapy Market Size and Growth Rate (2020-2025) & (M USD)

Figure 76. Southeast Asia Tumor Immunity Therapy Sales and Growth Rate (2020-2025) & (K MT)

Figure 77. Southeast Asia Tumor Immunity Therapy Market Size and Growth Rate

(2020-2025) & (M USD)

Figure 78. South America Tumor Immunity Therapy Sales and Growth Rate (K MT)

Figure 79. South America Tumor Immunity Therapy Sales Market Share by Country in 2024

Figure 80. South America Tumor Immunity Therapy Market Size and Growth Rate (M USD)

Figure 81. South America Tumor Immunity Therapy Market Size Market Share by Country in 2024

Figure 82. Brazil Tumor Immunity Therapy Sales and Growth Rate (2020-2025) & (K MT)

Figure 83. Brazil Tumor Immunity Therapy Market Size and Growth Rate (2020-2025) & (M USD)

Figure 84. Argentina Tumor Immunity Therapy Sales and Growth Rate (2020-2025) & (K MT)

Figure 85. Argentina Tumor Immunity Therapy Market Size and Growth Rate (2020-2025) & (M USD)

Figure 86. Columbia Tumor Immunity Therapy Sales and Growth Rate (2020-2025) & (K MT)

Figure 87. Columbia Tumor Immunity Therapy Market Size and Growth Rate (2020-2025) & (M USD)

Figure 88. Middle East and Africa Tumor Immunity Therapy Sales and Growth Rate (K MT)

Figure 89. Middle East and Africa Tumor Immunity Therapy Sales Market Share by Region in 2024

Figure 90. Middle East and Africa Tumor Immunity Therapy Market Size and Growth Rate (M USD)

Figure 91. Middle East and Africa Tumor Immunity Therapy Market Size Market Share by Region in 2024

Figure 92. Saudi Arabia Tumor Immunity Therapy Sales and Growth Rate (2020-2025) & (K MT)

Figure 93. Saudi Arabia Tumor Immunity Therapy Market Size and Growth Rate (2020-2025) & (M USD)

Figure 94. UAE Tumor Immunity Therapy Sales and Growth Rate (2020-2025) & (K MT)

Figure 95. UAE Tumor Immunity Therapy Market Size and Growth Rate (2020-2025) & (M USD)

Figure 96. Egypt Tumor Immunity Therapy Sales and Growth Rate (2020-2025) & (K MT)

Figure 97. Egypt Tumor Immunity Therapy Market Size and Growth Rate (2020-2025) & (M USD)

Figure 98. Nigeria Tumor Immunity Therapy Sales and Growth Rate (2020-2025) & (K MT)

Figure 99. Nigeria Tumor Immunity Therapy Market Size and Growth Rate (2020-2025) & (M USD)

Figure 100. South Africa Tumor Immunity Therapy Sales and Growth Rate (2020-2025) & (K MT)

Figure 101. South Africa Tumor Immunity Therapy Market Size and Growth Rate (2020-2025) & (M USD)

Figure 102. Global Tumor Immunity Therapy Production Market Share by Region (2020-2025)

Figure 103. North America Tumor Immunity Therapy Production (K MT) Growth Rate (2020-2025)

Figure 104. Europe Tumor Immunity Therapy Production (K MT) Growth Rate (2020-2025)

Figure 105. Japan Tumor Immunity Therapy Production (K MT) Growth Rate (2020-2025)

Figure 106. China Tumor Immunity Therapy Production (K MT) Growth Rate (2020-2025)

Figure 107. Global Tumor Immunity Therapy Sales Forecast by Volume (2020-2033) & (K MT)

Figure 108. Global Tumor Immunity Therapy Market Size Forecast by Value (2020-2033) & (M USD)

Figure 109. Global Tumor Immunity Therapy Sales Market Share Forecast by Type (2026-2033)

Figure 110. Global Tumor Immunity Therapy Market Share Forecast by Type (2026-2033)

Figure 111. Global Tumor Immunity Therapy Sales Forecast by Application (2026-2033)

Figure 112. Global Tumor Immunity Therapy Market Share Forecast by Application (2026-2033)

I would like to order

Product name: Global Tumor Immunity Therapy Market Research Report 2025(Status and Outlook)

Product link: <https://marketpublishers.com/r/G3FF11053685EN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G3FF11053685EN.html>